CMRX Chimerix, Inc.

5.95
-0.02  -0.34%
Previous Close 5.97
Open 5.94
Price To book 0.96
Market Cap 275.57M
Shares 46,315,000
Volume 348,598
Short Ratio 5.20
Av. Daily Volume 500,379

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b to be initiated late 2017.
Brincidofovir
BK virus
Phase 2b to be initiated late 2017.
Brincidofovir
Cytomegalovirus (CMV)
Phase 3 interim analysis released May 2016. Final data to be presented 1Q 2017.
Brincidofovir - Advise trial
Adenovirus Infection
Phase 3 discontinued following poor data from SUPPRESS trial
Brincidofovir - SURPASS
Cytomegalovirus (CMV) infection
Phase 3 endpoints not met December 2015
Brincidofovir - SUPPRESS
Cytomegalovirus (CMV) infection following an allogeneic hematopoietic stem cell transplant (HSCT)
Phase 3 discontinued following poor data from SUPPRESS trial
Brincidofovir - SUSTAIN
Cytomegalovirus (CMV) infection

Latest News

  1. 5 Breakout Stocks for Superior Returns
  2. Will Chimerix (CMRX) Continue to Surge Higher?
  3. Falling Earnings Estimates Signal Weakness Ahead for Agios Pharmaceuticals (AGIO)
  4. Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects
  5. CHIMERIX INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  6. Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects
  7. Chimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technology Officer
  8. Chimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technology Officer
  9. Chimerix to Present at the 35th Annual J.P. Morgan Healthcare Conference
  10. Should You Buy Beigene Ltd (ADR) (BGNE)?
  11. Here is What Hedge Funds Think About Chimerix Inc (CMRX)
  12. ETFs with exposure to Chimerix, Inc. : December 5, 2016
  13. CHIMERIX INC Financials
  14. ETF’s with exposure to Chimerix, Inc. : November 10, 2016
  15. Chimerix, Inc. :CMRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016
  16. Chimerix to Present at Upcoming Investor Conferences
  17. Edited Transcript of CMRX earnings conference call or presentation 7-Nov-16 1:30pm GMT
  18. CHIMERIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  19. Chimerix Announces Third Quarter 2016 Financial Results
  20. Chimerix to Announce Third Quarter 2016 Financial Results on November 7, 2016